Twin Peaks Wealth Advisors’s Novavax NVAX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7	Closed	-$57	–	1533
2026 Q1	$57	Buy	+7	New	+$63	﹤0.01%	2293
2025 Q3	–	Sell	-12	Closed	-$102	–	1452
2025 Q2	$102	Buy	+12	New	+$79	﹤0.01%	2111

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Twin Peaks Wealth Advisors's NVAX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Novavax (NVAX) in Q2 2026, closing a stake of 7 shares — an estimated $57 sold.

Twin Peaks Wealth Advisors first reported a position in NVAX in Q2 2025 and held it in 2 quarters. The position peaked at $102 in Q2 2025. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Novavax position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 7 Novavax shares in Q2 2026, an estimated $57.
Twin Peaks Wealth Advisors first reported a position in Novavax in Q2 2025 and held it in 2 quarters.
Twin Peaks Wealth Advisors's Novavax position peaked at $102 in Q2 2025.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.